Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Aug 15, 2024; 16(8): 3481-3495
Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3481
Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3481
Figure 1 The illustrated flowchart of selecting patient for comparing between camrelizumab plus apatinib and hepatic artery infusion chemotherapy alone and camrelizumab plus apatinib and hepatic artery infusion chemotherapy combined with microwave ablation treatment in patients with advanced hepatocellular carcinoma.
HCC: Hepatocellular carcinoma; MWA: Microwave ablation; TRIPLET: Camrelizumab plus apatinib and hepatic artery infusion chemotherapy; SR: Liver resection surgery; HAIC: Hepatic arterial infusion chemotherapy; PSM: Propensity score matching.
- Citation: Zuo MX, An C, Cao YZ, Pan JY, Xie LP, Yang XJ, Li W, Wu PH. Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(8): 3481-3495
- URL: https://www.wjgnet.com/1948-5204/full/v16/i8/3481.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i8.3481